阿扎胞苷治疗15例中高危骨髓增生异常综合征的疗效观察

高露; 王晓燕; 鲍立; 杨申淼; 主鸿鹄; 温磊; 路瑾; 江浩; 江倩; 黄晓军; 赖悦云

doi:10.13201/j.issn.1004-2806.2018.11.010

阿扎胞苷治疗15例中高危骨髓增生异常综合征的疗效观察

- 北京大学人民医院, 北京大学血液病研究所(北京, 100044)

详细信息

通讯作者: 赖悦云,E-mail:laiyueyun1008@sina.com

中图分类号: R733

收稿日期: 2018-03-30

The effects of Azacitidine treatment in 15 patients with intermediate-2 or high-risk myelodysplastic syndromes

- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, 100044, China

More Information

Corresponding author: LAI Yueyun, E-mail: laiyueyun1008@sina.com

Received Date: 30 March 2018

摘要

摘要: 目的:初步评估阿扎胞苷治疗中高危骨髓增生异常综合征(MDS)的安全性及有效性。方法:对入选的15例MDS患者应用阿扎胞苷75 mg·m^-2·d^-1皮下注射连续7 d,原则上每28 d为1个疗程,评估治疗期间患者对药物的耐受性及有效性。结果:15例患者总共完成133周期阿扎胞苷治疗。1例患者2个疗程结束出院后不明原因死亡无法评估疗效,1例患者1个疗程获得血液学改善,但因经济原因完成第2个疗程后终止治疗,其余13例患者均完成至少4周期治疗,4~6个疗程后评估疗效总有效率为38.5%(5/13)。其中3例(23.1%)完全缓解,2例(15.4%)骨髓完全缓解,3例疾病稳定,5例治疗失败。阿扎胞苷主要不良反应为血液学毒性,其中5例为3~4级血液学毒性;11例(73.3%)至少出现一次感染性发热;1例注射部位刺激性皮炎;1例间质性肺炎。结论:阿扎胞苷治疗中高危MDS总有效率接近40%,可以推荐用于不能进行造血干细胞移植的中高危MDS患者。
- 骨髓增生异常综合征 /
- 阿扎胞苷
Abstract: Objective:To evaluate the safety and effects of Azacitidine treatment in the patients with intermediate or high-risk myelodysplastic syndromes (MDS).Method:Fifteen selected patients with intermediate-2 or high-risk MDS were treated by subcutaneous injection of 75 mg·m^-2·d^-1 Azacitidine on days 1 to 7 of a 28-day cycle in principle.Patients were monitored for safety and adverse events and were evaluated for response during treatment.Result:In total,133 cycles of Azacitidine therapy were administered in 15 patients,1 case died of unknown reason after the second cycle of treatment,and the efficacy wasn't evaluated.Another case achieved a hematological improvement in the first cycle but the treatment was terminated after the second cycle due to economic reasons.All the remaining 13 patients completed at least 4 cycles of treatment.After 4-6 cycles of treatment,the overall response rate was 38.5% (5/13),including 3 cases (23.1%) achieved complete response and 2 cases (15.4%) achieved bone marrow complete response,3 cases maintained stable disease and 5 cases were treatment failure.The main adverse event of Azacitidine was hematological toxicity.Grade Ⅲ to Ⅳ of hematological toxicities happened in 5 patients.Infectious complications were seen in 11 out of 15 patients (73.3%) and in 23 cycles out of 133 (17.3%),while injection irritant dermatitis and interstitial pneumonia happened in one patient respectively.Conclusion:The overall response rate of Azacitidine treatment in intermediate-2 or high-risk MDS is nearly 40%,it could be recommended to intermediate-risk or high-risk MDS patients who cannot accept hematopoietic stem cell transplantation.
- myelodysplastic syndrome /
- Azacitidine

HTML全文

参考文献(13)

[1]	Musto P,Maurillo L,Spagnoli A,et al.Azacitidine for the treatment of lower risk myelodysplastic syndromes:a retrospective study of 74 patients enrolled in an Italian named patient program[J].Cancer,2010,116:1485-1494.
[2]	Silverman LR,Demakos EP,Peterson BL,et al.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:a study of the cancer and leukemia group B[J].J Clin Oncol,2002,20:2429-2440.
[3]	Fenaux P,Mufti GJ,Hellstrom-Lindberg E,et al.Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised,open-label,phase Ⅲ study[J].Lancet Oncol,2009,10:223-232.
[4]	Pleyer L,Burgstaller S,Stauder R,et al.Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia:comparison of French-American-British and World Health Organization classifications[J].J Hematol Oncol,2016,9:39-54.
[5]	Sekeres MA,Othus M,List AF,et al.Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia:North American Intergroup Study SWOG S1117[J].J Clin Oncol,2017,35:2745-2753.
[6]	崔晶,王景文,陈烨,等.阿扎胞苷治疗骨髓增生异常综合征转急性白血病1例并文献复习[J].临床血液学杂志,2008,21(5):270-272.
[7]	Cheson BD,Greenberg PL,Bennett JM,et al.Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J].Blood,2006,108:419-425.
[8]	Sébert M,Komrokji RS,Sekeres MA,et al.Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine[J].Leuk Res,2017,63:72-77.
[9]	Schuck A,Goette MC,Neukirchen J,et al.A retrospective study evaluating the impact of infectious complications during azacitidine treatment[J].Ann Hematol,2017,96:1097-1104.
[10]	Trubiano JA,Dickinson M,Thursky KA,et al.Incidence,etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes[J].Leuk Lymphoma,2017,58:2379-2386.
[11]	Merkel D,Filanovsky K,Gafter-Gvili A,et al.Predicting infections in high-risk patients with myelodyslastic syndrome acute myeloid leukemia treated with azacitidine:a retrospective multicenter study[J].Am J Hematol,2013,88:130-134.
[12]	Kuroda J,Shimura Y,Mizutani S,et al.Azacitidine-associated acute interstitial pneumonitis[J].Intern Med,2014,53:1165-1169.
[13]	Watanabe K,Doki N,Miura Y,et al.Toxic encephalopathy after exposure to azacitidine[J].Leuk Lymphoma,2014,16:1-10.